Overview
Nuwellis Q3 revenue fell 6% yr/yr but rose 29% sequentially
Net income for Q3 was $468,000, with EPS of $0.56
Company initiated manufacturing transition to focus on U.S. market growth
Outlook
Nuwellis focuses on U.S. market growth, exiting international operations
Company enhances product offerings with new 24-hour circuit and catheter
Nuwellis advances pediatric product development with NIH-funded collaboration
Result Drivers
CONSUMABLE UTILIZATION - Sequential revenue growth driven by increased consumable utilization and stronger U.S. console sales
PEDIATRIC PRODUCT DEVELOPMENT - Accelerated through NIH-funded collaboration and new U.S. patent
U.S. MARKET FOCUS - Manufacturing transition to KDI Precision Manufacturing and exit of international operations
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | $2.22 mln | ||
Q3 EPS | $0.56 | ||
Q3 Net Income | $468,000 | ||
Q3 Gross Profit | $1.45 mln | ||
Q3 Income from Operations | -$2.70 mln | ||
Q3 Pretax Profit | $468,000 |
Press Release: ID:nGNX7zQnQP
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)